Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development

Virchows Archiv

Volumn 465, Issue 4, 2014, Pages 473-485

  El Habr, Elias A ^a,b   Levidou, Georgia ^a   Trigka, Eleni Andriana ^a   Sakalidou, Joanna ^a   Piperi, Christina ^a   Chatziandreou, Ilenia ^a   Spyropoulou, Anastasia ^a   Soldatos, Rigas ^a   Tomara, Georgia ^a   Petraki, Kalliopi ^c   Samaras, Vassilis ^d   Zisakis, Athanasios ^d   Varsos, Vassilis ^d   Vrettakos, George ^c   Boviatsis, Efstathios ^e   Patsouris, Efstratios ^a   Saetta, Angelica A ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8246   (France)

^c METROPOLITAN HOSPITAL   (Greece)

^d RED CROSS HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

E17K; LY294002; MAPK; p 4E BP1; p p70S6K

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN AKT1; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 GAMMA; PROTEIN P85; PROTEIN P85 ALPHA; PROTEIN PIK3CA; PROTEIN S 100; STAT3 PROTEIN; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MTOR PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; STAT PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; BRAIN TUMOR; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASES; MALE; MENINGIOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84919331288     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1641-3     Document Type: Article

References (63)

1. Pham MH et al (2011) Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 30:E7
2. Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054
3. Jaskolski DJ et al (2013) Molecular alterations in meningiomas: association with clinical data. Clin Neuropathol 32:114–121
4. Barbera S et al (2013) Genetic changes with prognostic value in histologically benign meningiomas. Clin Neuropathol 32:311–317
5. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510
6. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16:S17–S27
7. Logue JS, Morrison DK (2012) Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 26:641–650
8. Vogt PK, Hart JR (2011) PI3K and STAT3: a new alliance. Cancer Discov 1:481–486
9. Gutierrez A, Look AT (2007) NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12:411–413
10. Wong GW, Knowles GC, Mak TW, Ferrando AA, Zúñiga-Pflücker JC (2012) HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRβ-selected mouse thymocytes. Blood 120:1439–1448
11. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104:5569–5574
12. Steelman LS et al (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy—implications for cancer and aging. Aging (Albany NY) 3:192–222
13. Carpten JD et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439–444
14. Chetram MA, Hinton CV (2012) PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 32:190–195
15. Korkolopoulou P et al (2012) A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 110:E1237–E1248
16. Rojo F et al (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13:81–89
17. Mair R, Morris K, Scott I, Carroll TA (2011) Radiotherapy for atypical meningiomas. J Neurosurg 115:811–819
18. Vranic A, Peyre M, Kalamarides M (2012) New insights into meningioma: from genetics to trials. Curr Opin Oncol 24:660–665
19. Pang JC et al (2006) Rare mutation of PIK3CA in meningiomas. Acta Neuropathol 111:284–285
20. Eom HS, Kim MS, Hur SY, Yoo NJ, Lee SH (2009) Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas. Acta Oncol 48:1084–1085
21. Brastianos PK et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289
22. Clark VE et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080
23. Juanpere N et al (2012) Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol 43:1573–1582
24. McCubrey JA et al (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3:1068–1111
25. Konstantinidou AE et al (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280–290
26. Beckner ME et al (2013) Low-level amplification of oncogenes correlates inversely with age for patients with nontypical meningiomas. World Neurosurg 79:313–319
27. Johnson MD, O’Connell MJ, Pilcher W, Reeder JE (2010) Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg 112:934–939
28. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS (2002) Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 97:668–675
29. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310
30. Xu Q et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552–5560
31. Johnson MD, O’Connell M, Vito F, Bakos RS (2009) Increased STAT3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol 92:129–136
32. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F (2006) Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 94:1906–1912
33. Badve S et al (2010) Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol 176:2139–2149
34. Dobashi Y et al (2009) Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115:107–118
35. Johnson SM et al (2010) Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210:767–778
36. Levidou G et al (2013) A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. J Am Acad Dermatol 69:375–384
37. Zhao N, Guo Y, Zhang M, Lin L (2010) AKT-mTOR signalling is involved in Notch-1-mediated gliomas cell survival and proliferation. Oncol Rep 23:1443–1447
38. Zhou J et al (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104:16158–16163
39. Pachow D et al (2013) mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 19:1180–1189
40. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66:5618–5623
41. Ge W, Ren J (2012) mTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism. J Cell Mol Med 16:616–626
42. Pende M et al (2004) S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124
43. Cohen JD et al (2011) ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 124:75–87
44. Rolli-Derkinderen M et al (2003) ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J Biol Chem 278:18859–18867
45. Korkolopoulou P et al (2012) Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 61:293–305
46. Xiao L, Wang YC, Li WS, Du Y (2009) The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28:152
47. Mawrin C et al (2005) Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074–4082
48. Jiang L et al (2011) Notch 1 expression is upregulated in glioma and is associated with tumor progression. J Clin Neurosci 18:387–390
49. Chung JH, Eng C (2005) Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 65:8096–8100
50. Gimm O et al (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693–1700
51. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumor suppressor. Nat Rev Mol Cell Biol 13:283–296
52. Choucair K et al (2012) PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 12:543
53. McMenamin ME et al (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291–4296
54. Mueller S et al (2012) PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol 14:1146–1152
55. Castellvi J et al (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801–1811
56. Adeyinka A et al (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8:1747–1753
57. Chadha KS et al (2006) Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13:933–939
58. Givant-Horwitz V et al (2003) Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91:160–172
59. Milde-Langosch K et al (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92:2206–2215
60. Mizumoto Y et al (2007) Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98:652–658
61. Schmitz KJ et al (2007) Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 450:151–159
62. Vicent S et al (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumors. Br J Cancer 90:1047–1052
63. Saetta AA et al (2011) Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. Virchows Arch 458:749–759